Regeneron Pharmaceuticals stock holds near its yearly range

Published on 09/22/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron Pharmaceuticals stock closed at a dated Nasdaq level on September 18, 2026, with valuation anchored by its latest reported period. Its product portfolio remains the key operating measure.

REGN, US75811P1003, Illustration mit AI erstellt.

Regeneron Pharmaceuticals stock (ISIN US75811P1003) remains framed by its latest available Nasdaq market level and the company's reported operating performance. The dated market reference is September 18, 2026, while the most recent financial period provides the basis for assessing revenue, earnings and pipeline execution.

Nasdaq level sets the frame

The stock's reference price and daily change are presented using the primary Nasdaq listing and the trading date supplied by market data. That venue matters because percentage changes, prior closes and valuation comparisons must refer to the same listing and currency.

For investors, the useful comparison is between the dated share price and the stock's 52-week range. A position closer to the upper end implies that expectations for the company's medicines and pipeline are already reflected more heavily in the valuation than a price near the lower end.

Latest results remain central

Regeneron's latest reported quarter within the relevant reporting window supplies the fundamental frame through revenue, earnings and operating margin. These figures are more informative than a generic description of the business because they show how commercial products and research spending translated into financial performance during the stated period.

The key comparison is the change against the prior-year period. Revenue growth, earnings per share and margin development must be read together: higher sales can support the stock only if profitability and investment in future products remain consistent with the reported results.

Stock remains tied to execution

Regeneron Pharmaceuticals stock therefore combines a dated Nasdaq quotation with a business case driven by product demand, clinical progress and the conversion of research into approved medicines. The next material checkpoint is the company's next explicitly scheduled reporting event when published in a source-covered financial calendar.

Regeneron Pharmaceuticals stock is framed by its Nasdaq price as of September 18, 2026, while the latest reported-period revenue and earnings figures provide the operating comparison.